Sara A. Hurvitz, MD, on Tucatinib and T-DM1 in Metastatic Breast Cancer: Key Findings From HER2CLIMB-02

Posted: Monday, March 25, 2024

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Center, University of Washington, discusses some of the practical considerations that stem from phase III data of the HER2CLIMB-02 trial, which showed that combining tucatinib and trastuzumab emtansine (T-DM1) improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases).

---